Abstract 2137P
Background
Performance ECOG status and staging are described as prognostic factors in oncologic outpatients while nutritional assessment can impact survival in both outpatients and inpatients. The aim of this study was to describe the Charslon Comorbidity Index (CCI), the nutritional status, the impact of opioid therapy and psycho-oncology and palliative care unit intervention for hospitalized cancer patients (pts).
Methods
A prospective multicentric study of pts hospitalized between January 2020 February 2022 at Vall d’Hebron and Sant Pau Hospitals [Plantology database] in Spain. Demographic and clinical variables such as CCI, laboratory results and nutritional status were collected at admission. Prognostic Nutritional Index (PNI) was calculated at admission. Quality of life (QoL) was collected through the EORTC-QLQ30 v.3 questionnaire. Statistical analysis was performed with SPSS v.29 (Log rank, Chi-square, Student’s t-test were used).
Results
A total of 1.431 patients (median age 66 years, 53.2% males) were included with a median of 9 days hospitalized. With a follow-up of 15 months, the median survival was 4.67 months after admission. Most pts (91.6%) had severe comorbidity (CCI ≥ 5 points) related to a lower survival (4.5 vs 12.8 months, p<0.001). A positive chair stand test for sarcopenia (12.2%) was associated with reduced survival (3.5 vs 9.1 months, p<0.001). Pts with hypoalbuminemia (65.3%) presented lower survival (3.5 vs 8.4 months, p<0.001). In addition, the PNI stratified 59.5% pts with serious malnutrition (PNI <40) linked to reduced survival (3.6 vs 7.9 months, p<0.001). Regarding supportive care, pts under opioid therapy (39.6%) had a higher QoL (mean EORTC QLQ-30 score of 73.4 vs 64.3, p<0.001). Palliative care team assessment and psycho-oncology intervention positively impacted in pts QoL (EORTC QLQ-30 of 74 vs 67.3, p<0.001, and 74.3 vs 65.2, p<0.001, respectively).
Conclusions
In hospitalized cancer pts, severe comorbidity, malnutrition and sarcopenia were associated with a reduced survival. Opioid therapy and psycho-oncological and palliative care unit intervention had a positive impact on the QoL of pts. Early supportive care interventions are key to improve symptomatology and preserve QoL of hospitalized cancer pts.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
VHIO.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2237P - Avelumab (AVE), cetuximab (CET) and irinotecan (IRI) for treatment refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC): Translational analyses of the AVETUXIRI phase II trial
Presenter: Nicolas Huyghe
Session: Poster session 07
2238P - Tebentafusp reprograms immunosuppressive tumor-associated M2 macrophages towards anti-tumoral M1 macrophages
Presenter: Josep M. Piulats
Session: Poster session 07
2239P - Gene expression profiling in tumors with and without tertiary lymphoid structures across cancer-types
Presenter: Elia Segui Solis
Session: Poster session 07
2240P - Novel genetic markers associated with immune checkpoint inhibitor induced immune-related adverse events
Presenter: Ik Shin Chin
Session: Poster session 07
2241P - A novel 89Zr-anti-PD-1 immuno-PET-CT may predict response to PD-1 inhibitors and improve response assessment in a lung cancer murine model receiving immunotherapy
Presenter: Ander Puyalto
Session: Poster session 07
2242P - Engineering immune-cell targeting nanoparticles for precise delivery of loaded-cargo and enhanced immunotherapy efficacy
Presenter: Na Kyeong Lee
Session: Poster session 07
2243P - Immune-modulating magnetic nanoparticles to enhance the immune response for the treatment of breast cancer metastasis and recurrence
Presenter: Jaesung Lim
Session: Poster session 07
2244P - Anti CTLA-4 and PD-1 monoclonal antibodies increases systemic SDF-1 and galectin-3 levels through NLRP3 and MyD-88 pathways in preclinical models
Presenter: Vincenzo Quagliariello
Session: Poster session 07
2245P - Graphene oxide: A promising platform for delivery of cancer immunotherapy
Presenter: Sorayut Chattrakarn
Session: Poster session 07
2246P - Tumor-infiltrating lymphocites and gene expression across multiple cancer-types: A translational analysis from the SOLTI-1904-ACROPOLI study
Presenter: Elia Segui Solis
Session: Poster session 07